Business
Admission and Total Voting Rights
Admission and Total Voting Rights.
About this update from Kanabo Group Plc
[{"type":"text","content":"\n\n\n26 July 2023\nKanabo Group PLC\n(\"Kanabo\" or the \"Company\")\n \nAdmission and Total Voting Rights\n \nThe Company announces today, 26 July 2023, 18,749,999 number of ordinary shares were admitted to trading on the Standard List of the London Stock Exchange (\"Admission\")\n \nFollowing Admission, for the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, Kanabo announces that the Company has 630,427,870 ordinary shares of 2.5p each in issue (\"Ordinary Shares\"), each share carrying the right to one vote. The figure of 630,427,870 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.\n \nThe Directors of the Company accept responsibility for the contents of this announcement.\n \n \nFor further information, please visit http://www.kanabogroup.com/ or contact the following:\n \nEnquiries:\n \n\n\n\nKanabo Group plc\nAvihu Tamir, Chief Executive Officer\nAssaf Vardimon, Chief Financial Officer\nIan Mattioli, Non-Executive Chair of the Board\n \n\n\nvia Vigo Consulting\n+44 (0)20 7390 0230\n\n\n\n\nPeterhouse Capital Ltd (Financial Adviser and Broker)\nEran Zucker/ Lucy Williams / Charles Goodfellow\n \n\n\n+44 (0)20 7469 0930\n\n\n\n\nVigo Consulting (Financial Public Relations/Investor Relations)\nJeremy Garcia / Fiona Hetherington / Verity Snow\[email protected]\n\n\n +44 (0)20 7390 0230\n \n\n\n\n \n \nAbout Kanabo Group Plc\nKanabo Group Plc (LSE:KNB) is a healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.\n \nKanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The Company is a leader in ...